Application of ofloxacin or derivative thereof in preparation of extracellular vesicle secretion inhibitor

By using ofloxacin or its derivatives to inhibit the secretion of extracellular vesicles, combined with anti-PD-1 monoclonal antibody, the problem of lack of effective inhibition of extracellular vesicles in the prior art has been solved, and a variety of factors have been significantly improved The therapeutic effect of tumors, especially the inhibition of PD-L1+ extracellular vesicles, enhances the effect of immunotherapy.

CN119055657AInactive Publication Date: 2024-12-03WUHAN UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411167567.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The prior art lacks effective methods and strategies to inhibit extracellular vesicles secretion, especially the inhibition of specific subtypes of extracellular vesicles, which affects the therapeutic effect of various diseases.

Method used

The use of ofloxacin or its derivatives as an inhibitor of extracellular vesicles secretion, and by significantly inhibiting the secretion of total extracellular vesicles and specific subtypes of extracellular vesicles, combined with anti-PD-1 monoclonal antibody for anti-PD-1 Tumor treatment.

Benefits of technology

Ofloxacin significantly inhibits the secretion of extracellular vesicles of a variety of tumor cells, especially the secretion of PD-L1+ extracellular vesicles, improves the immunotherapy effect of tumors such as malignant melanoma and oral squamous cell carcinoma, and in animal models The content of extracellular vesicles in tumor tissue and circulating blood was significantly reduced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055657A_ABST
    Figure CN119055657A_ABST
Patent Text Reader

Abstract

The invention discloses an application of ofloxacin or a derivative thereof in preparation of an inhibitor for secretion of extracellular vesicles, and cell experiments prove that ofloxacin can obviously inhibit secretion of total extracellular vesicles of various cells and specific subtype extracellular vesicles. The ofloxacin can significantly inhibit the content of PD-L1 + extracellular vesicles in circulating blood of a B16F10 tumor-bearing mouse, and can also inhibit the content of PD-L1 + extracellular vesicles in circulating blood and local tumor tissues of a 4NQO-induced oral squamous cell carcinoma in-situ tumor model mouse. In addition, the ofloxacin and the anti-PD-1 monoclonal antibody are combined for use, so that the immunotherapy effect of malignant melanoma, oral squamous cell carcinoma and other tumors can be remarkably improved.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Application of levofloxacin antibiotic in preparation of sensitization drug for anticancer drugs and anticancer drug comprising levofloxacin antibiotic

    CN110755438A

  • Nanoparticles containing quinolone compound, preparation comprising nanoparticles containing quinolone compound and application of nanoparticles containing quinolone compound

    CN111374961A

  • Immune checkpoint inhibitor and application

    CN114652814A